Alexander Miron

Papers

1

Total Citations

42

H-Index

1

About

Alexander Miron is a leading translational cancer researcher whose work focuses on identifying blood-based biomarkers for early cancer detection and monitoring therapeutic response. His most-cited study, "Declining Plasma Fibrinogen Alpha Fragment Identifies HER2-Positive Breast Cancer Patients and Reverts to Normal Levels after Surgery" (2006, 42 citations), pioneered a novel approach to address a critical gap in breast cancer diagnostics. At the time, no simple blood test existed to complement radiological screening for HER2-positive breast cancer, a particularly aggressive subtype. Miron’s team used automated proteomic screening of plasma specimens to discover that a specific fibrinogen alpha fragment could reliably identify HER2-positive patients and, remarkably, returned to normal levels after tumor removal. This work demonstrated the potential of circulating protein fragments as dynamic, noninvasive biomarkers for both diagnosis and surgical efficacy. By bridging proteomics and clinical oncology, Miron’s research has laid groundwork for liquid biopsy strategies that could reduce reliance on invasive tissue biopsies. His contributions underscore the power of combining high-throughput screening with clinical validation, offering hope for earlier detection and personalized monitoring in breast cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
42
Total Citations
42
Avg Citations/Paper
🏆 Most Cited Paper
Declining Plasma Fibrinogen Alpha Fragment Identifies HER2-Positive Breast Cancer Patients and Reverts to Normal Levels after Surgery
42 citations · 2006
📈 Most Prolific Year: 2006 (1 Papers)
🤝 Key Collaborators: 7

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago